

# Screening for chronic obstructive pulmonary disease (COPD) in patients hospitalized with chronic complex diseases. Utility of FEV1/FEV6 index for the diagnosis of chronic obstructive pulmonary disease, and prognostic implications

<b>Submission date</b> 23/05/2019	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 28/05/2019	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 14/06/2023	<b>Condition category</b> Respiratory	<input checked="" type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Chronic respiratory diseases account for an important percentage of multimorbidity, although compared with other chronic diseases, pulmonary disorders are often underdiagnosed. The causes of this misdiagnosis are, among others, the lack of suspicion and the need to perform valid spirometry (a measurement of the speed of the air that is exhaled) to confirm the diagnosis of many of them, such as COPD. Although spirometry is a simple and widely available technique, its performance in frail elderly patients can be difficult, especially due to the inability to maintain expiratory flow until complete exhalation. Depending on the population studied, between 20 and 80% of elderly patients are unable to complete satisfactory spirometry. In recent years, several handheld spirometers have been developed. Usually, these spirometers measure the FEV1/FEV6 ratio, requiring less effort and allowing the recovery of the 25% of patients unable to complete forced vital expiration. These devices have proven useful in the screening of respiratory obstruction and have shown an excellent correlation with conventional spirometry. However, current evidence of the utility of FEV1/FEV6 for the diagnosis of airway obstruction in multimorbid patients hospitalized for decompensation of chronic diseases is scarce.

Our main objective was to study the utility and reliability of FEV1/FEV6 in the diagnosis of pulmonary obstruction in patients hospitalized with multimorbidity, and the variables associated with the inability to successfully perform valid manoeuvres to determine the FEV1/FEV6 with COPD-6 and FEV1/FVC with conventional spirometry.

### Who can participate?

Patients hospitalized for any cause in the complex chronic patient care unit at University Hospital Mutua de Terrassa with  $\geq 2$  chronic diseases.

What does the study involve?

On the last day of hospitalization patients or their caregivers completed a questionnaire that included medical and socioeconomic variables, smoking history, prior diagnosis of chronic respiratory disease, results of the most recent spirometry if available, and domiciliary treatment. Measurement of the functional parameters, FEV1, FEV6, and FEV1/FEV6 ratio, was performed the last day of hospitalization, using the portable COPD-6 device and a portable spirometer.

What are the possible benefits and risks of participating?

The study does not suppose any risk to the patient since the maneuvers (FEV1/FEV6 and standard spirometry) are innocuous and the rest of the data are already usually collected in our unit according to good clinical practice. The potential benefits are the reduction of underdiagnosis in these patients and the possibility of initiating bronchodilator treatment in patients with airflow obstruction.

Where is the study run from?

Complex chronic patient care unit Universitary Hospital Mutua de Terrassa, Spain.

When is the study starting and how long is it expected to run for?

September 2017 to May 2018

Who is funding the study?

Complex chronic patient care unit Universitary Hospital Mutua de Terrassa, Spain.

Who is the main contact?

Prof. Pere Almagro

[palmagro@mutuaterrassa.cat](mailto:palmagro@mutuaterrassa.cat)

## Contact information

**Type(s)**

Scientific

**Contact name**

Prof Pere Almagro

**ORCID ID**

<http://orcid.org/0000-0002-8476-4942>

**Contact details**

Pza Dr Robert 5

Terrassa

Barcelona

Spain

08226

937365050

[palmagro@mutuaterrassa.cat](mailto:palmagro@mutuaterrassa.cat)

## Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

PAM-000-2017-01

## Study information

### Scientific Title

Screening for COPD in patients hospitalized with chronic complex diseases. Utility of FEV1/FEV6 index for the diagnosis of chronic obstructive pulmonary disease, and prognostic implications.

### Study objectives

1. Patients hospitalized in the care unit for chronic complex patients from the Internal Medicine department of the University Hospital Mutua de Terrassa will present a high prevalence of pulmonary obstruction measured by FEV1/FEV6 index, and this will be confirmed with a subsequent standard spirometric test.
2. The presence of cognitive impairment (measured with short portable Pfeiffer test, Global Deterioration Scale (GDS), MMSE, and intersecting pentagon copying component of the MMSE) or functional impairment (measured with the Barthel index) will be associated with a lower probability of completely valid determination of FEV1/FEV6.
3. The presence of pulmonary obstruction measured by FEV1/FEV6 index and confirmed by subsequent standard spirometry, and the severity of the disease assessed with the post-bronchodilator FEV1%, will be associated with a worse prognosis in the medium term (1-year) defined as hospital readmission or death after hospital discharge.
4. Of the patients able to undergo measurement of the FEV1/FEV6 index, approximately 20% cannot complete a quality spirometry according to the criteria of the American Thoracic Society.
5. Patients with a greater burden of comorbidity – defined according to the functional definition of polypathological patient criteria of the Andalusia Health Department and the Charlson index – will present a greater prevalence of obstructive pulmonary criteria measured by the FEV1/FEV6 index and subsequently confirmed by complete spirometry.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 31/05/2017, Ethical research committee, Hospital Universitario Mutua de Terrassa (Dr. Jordi Nicolas Pico, C/ Sant Antoni 39, Terrassa 08221, Barcelona, Spain; 34-937365050 ext 11032; jnicolas@mutuaterrassa.cat)

### Study design

Prospective observational cohort study

### Primary study design

Observational

## Secondary study design

Cohort study

## Study setting(s)

Hospital

## Study type(s)

Screening

## Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

## Health condition(s) or problem(s) studied

Chronic obstructive pulmonary disease in patients with multimorbidity

## Interventions

On the last day of hospitalization patients or their caregivers completed a questionnaire that included medical and socioeconomic variables, smoking history, prior diagnosis of chronic respiratory disease, results of the most recent spirometry if available, and domiciliary treatment. Multimorbidity assessment was evaluated using the multimorbidity classification of the Andalusia Health Department, the Charlson index and a scale for other comorbid conditions not included in the Charlson index. Physical functional status was assessed with the Barthel index, while cognitive status was measured using the Pfeiffer test and the Mini-Mental Cognitive Examination in the Spanish version of Lobo et al.

Measurement of the functional parameters, FEV1, FEV6, and FEV1/FEV6 ratio, was performed the last day of hospitalization, using the portable COPD-6 device (model 4000, Vitalograph Ltd., Ennis, Co. Clare, Ireland) and a portable spirometer. (Datoespri micro, Sibelmed, Barcelona Spain).

## Intervention Type

Other

## Primary outcome measure

Prevalence and underdiagnosis of obstructive pulmonary disease, as measured by FEV1 / FEV6 and confirmed by subsequent spirometry in patients hospitalized in the complex chronic patient care unit. Measurement of the functional parameters, FEV1, FEV6, and FEV1/FEV6 ratio, was performed the last day of hospitalization, using the portable COPD-6 device (model 4000, Vitalograph Ltd., Ennis, Co. Clare, Ireland) and a portable spirometer. (Datoespri micro, Sibelmed, Barcelona Spain).

## Secondary outcome measures

Variables are associated with the inability to successfully perform valid maneuvers to determine the FEV1/FEV6.

1. A questionnaire that included medical and socioeconomic variables, smoking history, prior diagnosis of chronic respiratory disease, results of the most recent spirometry if available, and domiciliary treatment.
2. Multimorbidity assessment was evaluated using the multimorbidity classification of the Andalusia Health Department, the Charlson index and a scale for other comorbid conditions not included in the Charlson index.
3. Physical functional status was assessed with the Barthel index.

4. Cognitive status was measured using the Pfeiffer test and the Mini-Mental Cognitive Examination in the Spanish version of Lobo et al.

All measures were completed on the last day of hospitalisation.

**Overall study start date**

15/01/2017

**Completion date**

31/05/2019

## **Eligibility**

**Key inclusion criteria**

Patients hospitalized for any cause in the complex chronic patient care unit at University Hospital Mutua de Terrassa with  $\geq 2$  chronic diseases according to the functional definition of poly pathological patient of the Andalusia Health Department.

**Participant type(s)**

Patient

**Age group**

Senior

**Sex**

Both

**Target number of participants**

200

**Total final enrolment**

184

**Key exclusion criteria**

1. No written informed consent to participation in the study.
2. Death during hospitalization.
3. Other reasons, apart from cognitive or functional impairment, which prevent the realization of FEV1/FEV6 (e.g., tracheotomy, facial paralysis....)

**Date of first enrolment**

01/09/2017

**Date of final enrolment**

31/05/2018

## **Locations**

**Countries of recruitment**

Spain

**Study participating centre**

Complex chronic patient care unit University Hospital Mutua de Terrassa  
Pza. Dr. Robert 5  
Terrassa  
Spain  
08226

## Sponsor information

**Organisation**

Mutua Terrassa

**Sponsor details**

Hospital Universitario Mutua de Terrassa  
Terrassa  
Spain  
08221  
34-937365050  
palmagro2@mutuaterrassa.cat

**Sponsor type**

Hospital/treatment centre

**Website**

<https://www.mutuaterrassa.com>

**ROR**

<https://ror.org/02h74qa12>

## Funder(s)

**Funder type**

Other

**Funder Name**

Investigator initiated and funded

## Results and Publications

**Publication and dissemination plan**

Planned publication in a high-impact peer-reviewed journal.

## Intention to publish date

31/05/2019

## Individual participant data (IPD) sharing plan

All data generated or analysed during this study will be included in the subsequent results publication.

## IPD sharing plan summary

Other

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	protocol	01/07/2017		Yes	No
<a href="#">Results article</a>	results	02/08/2019	12/05/2020	Yes	No
<a href="#">Dataset</a>		02/08/2019	14/06/2023	No	No